Clear Cell Renal Cell Carcinoma
Key Points
Key Points
- Kidney cancer will be diagnosed in 79,000 U.S. patients in 2022 and will account for 13,920 deaths.
- Opportunities for extended survival and even durable disease control in the metastatic setting have recently appeared as novel classes of therapeutics, reshaping the trajectory of this cancer.
- This rapid evolution has paved the way for this first set of comprehensive guidelines for treating metastatic clear cell renal cell carcinoma (ccRCC).
Diagnosis
...gnosis...
...on 1.1The diagnosis of metastatic clear...
...ndation 1.2Radiographic diagnosis o...
Treatment
...eatmen...
...ndation 2.1Select patients (see Pract...
...ion 3.1Select patients with metastatic clear cel...
Figure 1. First-Line Treatmenta Select...
...mendation 3.2All patients with met...
...mmendation 3.3Patients with favorable risk disea...
...commendation 3.4Select patients with metas...
...on 3.5The use of high dose interleuki...
...endation from 2023 Rapid Recommendat...
...mmendation 3.6Treatment with IpiNivoCabo is...
...4.1Nivolumab or cabozantinib should...
...tion 4.2Patients progressing on comb...
Recommendation 4.3Patients who progress...
...ecommendation 4.4For patients on immunotherap...
...mendation 5.1For patients with low volume metasta...
...dation 5.2For patients undergoing com...
...tion 6.1.1Patients with symptomatic bone metas...
...n 6.1.2Patients with bone metastases from meta...
...ure 2. Second-Line or Greater Treatment...
...re 3. Metastases-Directed Treat...
...ndation 6.1.3No recommendation regarding op...
Recommendation 6.2.1Patients with brain metast...
...endation 6.2.2No recommendation regardi...
Recommendation 6.3Patients with metastatic cl...
...ure 4. Special Patient Subtypes...
...es that cancer clinical trials are vital to i...